文献速递预防保健、筛查与疫苗慢病管理

美国成人新冠mRNA疫苗对中重症保护随时间衰减:VISION网络检测阴性病例对照研究

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study.
PubMed 文献 · BMJ · 2022-10-03

奥密克戎期第三剂后2个月内住院保护为89%,4-5个月降至66%;急诊/紧急护理保护从83%降至46%。各亚组均见衰减,免疫抑制者更明显,第四剂后多数组保护回升。

要点

  • 奥密克戎期第三剂后住院保护2个月内89%,4-5个月降至66%
  • 急诊/紧急护理保护从83%降至4-5个月时46%
  • 各亚组均见衰减,免疫抑制者更明显,第四剂后多数组保护回升

核心结论

  • mRNA疫苗对中重症新冠的保护随接种后时间衰减,支持基础免疫后加强接种及考虑额外加强剂。

主要发现

  • 奥密克戎期第三剂后2个月内住院疫苗保护为89%(95%CI 88%至90%),4-5个月降至66%(63%至68%)。
  • 奥密克戎期三剂对急诊/紧急护理就诊保护初始为83%(82%至84%),4-5个月降至46%(44%至49%)。
  • 所有亚组均见衰减,包括年轻成人和非免疫抑制者,免疫抑制者衰减更明显。
  • 在推荐第四剂的人群中,多数组第四剂后疫苗保护回升。

临床怎么用

  • 对成人完成基础免疫后应按推荐加强接种,以维持对中重症新冠的保护。
  • 对免疫抑制者等衰减更明显人群,可考虑额外加强剂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, and by age and immunocompromised status. DESIGN: Test negative case-control study. SETTING: Hospitals, emergency departments, and urgent care clinics in 10 US states, 17 January 2021 to 12 July 2022. PARTICIPANTS: 893 461 adults (≥18 years) admitted to one of 261 hospitals or to one of 272 emergency department or 119 urgent care centers for covid-like illness tested for SARS-CoV-2. MAIN OUTCOME MEASURES: The main outcome was waning of vaccine effectiveness with BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) vaccine during the omicron and delta periods, and the period before delta was dominant using logistic regression conditioned on calendar week and geographic area while adjusting for age, race, ethnicity, local virus circulation, immunocompromised status, and likelihood of being vaccinated. RESULTS: 45 903 people admitted to hospital with covid-19 (cases) were compared with 213 103 people with covid-like illness who tested negative for SARS-CoV-2 (controls), and 103 287 people admitted to emergency department or urgent care with covid-19 (cases) were compared with 531 168 people with covid-like illness who tested negative for SARS-CoV-2. In the omicron period, vaccine effectiveness against covid-19 requiring admission to hospital was 89% (95% confidence interval 88% to 90%) within two months after dose 3 but waned to 66% (63% to 68%) by four to five months. Vaccine effectiveness of three doses against emergency department or urgent care visits was 83% (82% to 84%) initially but waned to 46% (44% to 49%) by four to five months. Waning was evident in all subgroups, including young adults and individuals who were not immunocompromised; although waning was morein people who were immunocompromised. Vaccine effectiveness increased among most groups after a fourth dose in whom this booster was recommended. CONCLUSIONS: Effectiveness of mRNA vaccines against moderate and severe covid-19 waned with time after vaccination. The findings support recommendations for a booster dose after a primary series and consideration of additional booster doses.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Ferdinands JM, Rao S, Dixon BE, et al. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022. PMID: 36191948. doi:10.1136/bmj-2022-072141

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。